Market Cap | 111.68M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -54.35M | Forward P/E | 70.00 | EPS next Y | - | 50D Avg Chg | -18.00% |
Sales | 21.74M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -52.00% |
Dividend | N/A | Price/Book | 0.49 | EPS next 5Y | - | 52W High Chg | -84.00% |
Recommedations | 2.00 | Quick Ratio | 2.08 | Shares Outstanding | 10.64M | 52W Low Chg | 7.00% |
Insider Own | 21.18% | ROA | -10.60% | Shares Float | 7.97M | Beta | -0.28 |
Inst Own | 27.25% | ROE | -24.87% | Shares Shorted/Prior | 109.67K/12.76K | Price | 0.70 |
Gross Margin | 40.61% | Profit Margin | -288.48% | Avg. Volume | 151,390 | Target Price | 60.00 |
Oper. Margin | -211.32% | Earnings Date | - | Volume | 232,840 | Change | 1.45% |
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.
Cantor Fitzgerald | Overweight | Apr 4, 24 |